retatrutide triple agonist glp-1 gip glucagon Synedica The Road towards Triple Agonists:

DOI: 10.1016/S0140-6736(26)00800-7

Treatment satisfaction significantly improved among GLP-1 users in six studies

For example, uncomfortable fullness has the potential to be reported as nausea by one participant, but not another

The time to build that infrastructure is before the volume compounds

BMI is an imperfect measure, but its still one of the tools clinicians and insurers use to determine eligibility

Integrative Potential and Clinical Insight From a functional medicine perspective, GLP-1, GLP-2, and VIP peptides could become adjunctive supports in MCAS and related conditions such as IBS, POTS, EhlersDanlos syndrome, chronic fatigue, and long COVID, where mast-celldriven neuroinflammation plays a central role